Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1964198 | 1.00 | TP53 (0.57) | TP53MAPTSMN1; SMN2LMNAKMT2A | |
| SCHEMBL1964009 | 0.82 | TP53 (0.74) | TP53MAPTSMN1; SMN2LMNAKMT2A | |
| SCHEMBL1964007 | 0.82 | TP53 (0.74) | TP53MAPTSMN1; SMN2LMNAKMT2A | |
| SCHEMBL1961562 | 0.78 | KMT2A (0.79) | TP53MAPTSMN1; SMN2LMNAKMT2A | |
| SCHEMBL1961563 | 0.78 | KMT2A (0.79) | TP53MAPTSMN1; SMN2LMNAKMT2A | |
| SCHEMBL1960455 | 0.77 | TP53 (0.70) | TP53MAPTSMN1; SMN2LMNAKMT2A | |
| SCHEMBL1960453 | 0.77 | TP53 (0.70) | TP53MAPTSMN1; SMN2LMNAKMT2A | |
| SCHEMBL12616056 | 0.73 | LMNA (0.65) | TP53MAPTSMN1; SMN2LMNAKMT2A | |
| SCHEMBL12566779 | 0.73 | TP53 (0.68) | TP53MAPTSMN1; SMN2LMNAKMT2A | |
| SCHEMBL12553526 | 0.72 | TP53 (0.67) | TP53MAPTSMN1; SMN2LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170224687-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES INC (US) | 2017-08-10 | — | — | US | disclosed |
| US-9486455-B2 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20140155417-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8552009-B2 | Substituted pyrimido 4.5-d pyrimidin-4-one compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. | 2013-10-08 | — | — | US | disclosed |
| US-20110151559-A1 | Compounds for Modulating TRPV3 Function | HYDRA BIOSCIENCES, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110144135-A1 | Compounds for Modulating TRPV3 Function | HYDRA BIOSCIENCES, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7893260-B2 | Substituted quinazolin-4-one compounds for antagonizing TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100152209-A1 | Compounds for Modulating TRPV3 Function | HYDRA BIOSCIENCES INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20090018147-A1 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES INC. (US) | 2009-01-15 | — | — | US | disclosed |
| WO-2008140750-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| EP-1954283-A2 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | Hydra Biosciences, Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070179164-A1 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| WO-2007056124-A2 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155417-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | TRPV3, TRPV1, TRPV4 | TP53 4750/4885MAPT 1751/4885SMN1; SMN2 2219/4885 |
| US-20090018147-A1 | Compounds for modulating TRPV3 function | TRPV3, TRPV1, TRPV4 | TP53 4750/4885MAPT 1751/4885SMN1; SMN2 2219/4885 |
| US-20100152209-A1 | Compounds for Modulating TRPV3 Function | TRPV3, TRPV1, TRPV4 | TP53 4750/4885MAPT 1751/4885SMN1; SMN2 2219/4885 |
| US-20070179164-A1 | Compounds for modulating TRPV3 function | TRPV3, TRPV1, TRPV4 | TP53 4750/4885MAPT 1751/4885SMN1; SMN2 2219/4885 |
| US-20170224687-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | TRPV3, TRPV1, TRPV4 | TP53 4750/4885MAPT 1751/4885SMN1; SMN2 2219/4885 |
| US-20110144135-A1 | Compounds for Modulating TRPV3 Function | TRPV3, TRPV1, TRPV4 | TP53 4750/4885MAPT 1751/4885SMN1; SMN2 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.